Document Detail

Efficacy of tacrolimus in infliximab-refractory progressive rheumatoid arthritis.
MedLine Citation:
PMID:  18802706     Owner:  NLM     Status:  MEDLINE    
We report a Japanese male patient with intractable rheumatoid arthritis (RA), in whom tacrolimus was effective ultimately. Five years before the admission he was diagnosed as RA, which was resistant to various disease-modifying anti-rheumatic drugs (DMARDs). Two years before, administration of infliximab was initiated although the medicine failed to control RA. In spite of the multiple joint replacement, the RA disease activity worsened. Tacrolimus (1.5 mg/day) was administered. Twenty-four weeks of tacrolimus treatment reduced the disease activity score for 28 joints-erythrocyte sedimentation rate from 7.44 to 3.65. Herein, we present a patient with RA, who was successfully treated by tacrolimus, and in whom infliximab was not effective. Tacrolimus may be one of the drugs for RA patients refractory to the conventional treatments including methotrexate or tumor necrosis factor inhibitors.
Kazuhiro Yokota; Yuji Akiyama; Yu Asanuma; Fumihiko Miyoshi; Kojiro Sato; Toshihide Mimura
Related Documents :
20436076 - Predictors of clinical response and radiographic progression in patients with rheumatoi...
21718756 - The biochemistry of asthma.
15370716 - Death rates and causes of death in patients with rheumatoid arthritis: a population-bas...
9310106 - Hla-b27 in french patients with rheumatoid arthritis.
9870636 - Persistent dysphagia after laser uvulopalatoplasty: a videoradiographic study of pharyn...
8183446 - Haemorrhagic pituitary tumours.
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2008-09-18
Journal Detail:
Title:  Rheumatology international     Volume:  29     ISSN:  1437-160X     ISO Abbreviation:  Rheumatol. Int.     Publication Date:  2009 Feb 
Date Detail:
Created Date:  2009-02-04     Completed Date:  2009-08-19     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8206885     Medline TA:  Rheumatol Int     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  459-61     Citation Subset:  IM    
Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma-gun, Saitama, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / therapeutic use*
Antirheumatic Agents / therapeutic use
Arthritis, Rheumatoid / drug therapy*,  therapy*
Disease Progression
Drug Resistance
Immunosuppressive Agents / administration & dosage,  adverse effects,  therapeutic use*
Middle Aged
Tacrolimus / administration & dosage,  adverse effects,  therapeutic use*
Treatment Outcome
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antirheumatic Agents; 0/Immunosuppressive Agents; 0/infliximab; 109581-93-3/Tacrolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Targeting the CD134-CD134L interaction using anti-CD134 and/or rhCD134 fusion protein as a possible ...
Next Document:  Occludin expression in goldfish held in ion-poor water.